Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
11.08
+0.28 (2.59%)
Jun 11, 2026, 3:44 PM EDT - Market open
Climb Bio Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.36 | 35.69 | 87.23 | 93.11 | 43.59 | 46.92 |
Short-Term Investments | 101.21 | 65.4 | 63.69 | 13.69 | 79.98 | 89.56 |
Cash & Short-Term Investments | 109.56 | 101.08 | 150.92 | 106.8 | 123.57 | 136.48 |
Cash Growth | 11.73% | -33.02% | 41.31% | -13.57% | -9.46% | 566.18% |
Other Current Assets | 3.84 | 4.77 | 3.95 | 3.46 | 10.83 | 11.77 |
Total Current Assets | 113.4 | 105.85 | 154.87 | 110.26 | 134.39 | 148.25 |
Net Property, Plant & Equipment | 0.7 | 0.79 | 0.69 | 0.2 | 0.47 | - |
Long-Term Investments | 36.74 | 59.57 | 61.61 | - | - | 24.92 |
Other Long-Term Assets | 1.53 | 1.53 | 0.02 | 0.02 | 0.13 | 0.07 |
Total Assets | 152.37 | 167.74 | 217.19 | 110.47 | 134.99 | 173.24 |
Accounts Payable | 0.86 | 2.27 | 0.71 | 0.07 | 0.75 | 1.4 |
Accrued Expenses | 2.95 | 4.46 | 4.07 | 2.43 | 5.05 | 4.63 |
Current Portion of Leases | 0.26 | 0.26 | 0.16 | 0.33 | 0.3 | - |
Total Current Liabilities | 4.07 | 6.98 | 4.93 | 2.83 | 6.1 | 6.03 |
Long-Term Leases | 0.22 | 0.29 | 0.38 | 0.02 | 0.18 | - |
Other Long-Term Liabilities | - | - | - | 0.02 | - | 0.01 |
Total Long-Term Liabilities | 0.22 | 0.29 | 0.38 | 0.04 | 0.18 | 0.01 |
Total Liabilities | 4.29 | 7.27 | 5.31 | 2.87 | 6.28 | 6.04 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-in Capital | 451.37 | 449.76 | 441.73 | 263.58 | 249.93 | 242.94 |
Accumulated Other Comprehensive Income | 0.16 | 0.44 | 0.02 | -0 | -0.36 | -0.12 |
Retained Earnings | -303.45 | -289.73 | -229.88 | -155.98 | -120.86 | -75.62 |
Total Common Shareholders' Equity | 148.09 | 160.48 | 211.88 | 107.6 | 128.72 | 167.2 |
Shareholders' Equity | 148.09 | 160.48 | 211.88 | 107.6 | 128.72 | 167.2 |
Total Liabilities & Equity | 152.37 | 167.74 | 217.19 | 110.47 | 134.99 | 173.24 |
Total Debt | 0.48 | 0.54 | 0.53 | 0.35 | 0.48 | 0 |
Net Cash (Debt) | 109.09 | 100.54 | 150.39 | 106.45 | 123.09 | 136.48 |
Net Cash Growth | 8.50% | -33.15% | 41.28% | -13.52% | -9.81% | 566.18% |
Net Cash Per Share | 1.60 | 1.48 | 3.12 | 3.94 | 4.68 | 11.13 |
Book Value | 148.09 | 160.48 | 211.88 | 107.6 | 128.72 | 167.2 |
Book Value Per Share | 2.18 | 2.37 | 4.40 | 3.98 | 4.89 | 13.64 |
Tangible Book Value | 148.09 | 160.48 | 211.88 | 107.6 | 128.72 | 167.2 |
Tangible Book Value Per Share | 2.18 | 2.37 | 4.40 | 3.98 | 4.89 | 13.64 |